ESMO open · 2026
Optimal clinicogenetic criteria for post-operative re-irradiation in recurrent glioblastoma: KROG 21-02.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Park S, Kim D, Yoon H I, Lee J H, Lim D H, Kim N, Song J H, Suh C-O, Wee C W, Kim I A
Аннотация
BACKGROUND: Patients with glioblastoma (GBM) often have disease progression after standard temozolomide-based chemoradiation. The benefits and optimal use of re-irradiation (re-RT) following re-operation (re-OP) in recurrent GBM (rGBM) remain uncertain. In this study, we assessed the efficacy and safety of post-operative re-RT in patients with isocitrate dehydrogenase-wild-type rGBM, aiming to identify survival benefits and determine clinicogenetic criteria for patient selection.
PATIENTS AND METHODS: Data from the Korean Radiation Oncology Group 21-02 retrospective study were evaluated, including 531 patients with rGBM from 2013 to 2019. A subset of 164 patients undergoing re-OP were analyzed for survival and benefits of post-operative re-RT. Additionally, 206 patients receiving re-RT, irrespective of re-OP, were evaluated for risks of radiation necrosis. The overall survival (OS) after re-OP was the primary endpoint. Statistical analyses included the Kaplan-Meier method and log-rank test for OS, Cox proportional hazards regression model for univariate and multivariate analyses, and the Fine-Gray competing risk model for assessing the risk of brain necrosis.
RESULTS: The median OS after re-OP was 13.4 months. Kaplan-Meier analysis revealed significantly better OS for those who received re-RT (17.6 months) than for those who did not (11.0 months; P = 0.002). Factors associated with improved OS included higher Karnofsky performance status scores, post-operative re-RT, and additional systemic therapy after re-OP. Factors associated with adverse outcomes included recurrence outside the initial RT field and homozygous deletion of CDKN2A/B. The incidence of grade 2 or higher RT necrosis was 5.8% among those undergoing both re-OP and post-operative re-RT.
CONCLUSION: Post-operative re-RT appears to be associated with enhanced survival and minimal toxicity in patients with rGBM following temozolomide chemoradiation. Our study suggests a novel clinicogenetic criterion for re-RT after re-OP in rGBM, which requires further validation.
PATIENTS AND METHODS: Data from the Korean Radiation Oncology Group 21-02 retrospective study were evaluated, including 531 patients with rGBM from 2013 to 2019. A subset of 164 patients undergoing re-OP were analyzed for survival and benefits of post-operative re-RT. Additionally, 206 patients receiving re-RT, irrespective of re-OP, were evaluated for risks of radiation necrosis. The overall survival (OS) after re-OP was the primary endpoint. Statistical analyses included the Kaplan-Meier method and log-rank test for OS, Cox proportional hazards regression model for univariate and multivariate analyses, and the Fine-Gray competing risk model for assessing the risk of brain necrosis.
RESULTS: The median OS after re-OP was 13.4 months. Kaplan-Meier analysis revealed significantly better OS for those who received re-RT (17.6 months) than for those who did not (11.0 months; P = 0.002). Factors associated with improved OS included higher Karnofsky performance status scores, post-operative re-RT, and additional systemic therapy after re-OP. Factors associated with adverse outcomes included recurrence outside the initial RT field and homozygous deletion of CDKN2A/B. The incidence of grade 2 or higher RT necrosis was 5.8% among those undergoing both re-OP and post-operative re-RT.
CONCLUSION: Post-operative re-RT appears to be associated with enhanced survival and minimal toxicity in patients with rGBM following temozolomide chemoradiation. Our study suggests a novel clinicogenetic criterion for re-RT after re-OP in rGBM, which requires further validation.